CoLucid Pharmaceuticals, Inc.
CLCD
CLCD was delisted on the 28th of February, 2017.
56 hedge funds and large institutions have $472M invested in CoLucid Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 4 closing their positions.
925% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 4
921% more capital invested
Capital invested by funds: $46.3M → $472M (+$426M)
500% more funds holding in top 10
Funds holding in top 10: 1 → 6 (+5)
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
180% more funds holding
Funds holding: 20 → 56 (+36)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$11.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.6M |
| 4 |
PA
Perceptive Advisors
New York
|
+$8.16M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.48M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$650K |
| 3 |
SG Americas Securities
New York
|
-$464K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$368K |
| 5 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$178K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Wells Fargo
San Francisco,
California
| $201K | +$77.9K | +5,269 | New |
|
52
Bank of America
Charlotte,
North Carolina
| $200K | +$77.7K | +5,258 | New |
|
|
AG
53
Advisor Group
Phoenix,
Arizona
| $29K | – | – | – |
|
54
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $25K | – | – | – |
|
|
BIM
55
BlackRock Investment Management
Wilmington,
Delaware
| $20K | -$636 | -43 | -8% |
|
|
PCM
56
Prelude Capital Management
New York
| $16K | +$6.06K | +410 | New |
|
57
UBS Group
Zurich,
Switzerland
| $8K | +$2.96K | +200 | New |
|
|
58
SG Americas Securities
New York
| – | -$464K | -56,769 | Closed |
|
|
UOC
59
UBS O'Connor
Chicago,
Illinois
| – | -$368K | -44,994 | Closed |
|
|
MAM
60
MPM Asset Management
Boston,
Massachusetts
| – | -$178K | -21,806 | Closed |
|
61
Acadian Asset Management
Boston,
Massachusetts
| – | -$7K | -840 | Closed |
|
CLCD Hedge Fund Activity: Q3 2016 in Review
56 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q3 2016, worth a combined $472M — up 921% from $46.3M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CLCD positions and 4 closed out — a net gain of 37 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $17.1M. The largest seller was Sphera Funds Management, cutting an estimated $1.48M.
- 56 institutional investors held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q3 2016, up from 20 in Q2 2016.
- Funds reported $472M of CoLucid Pharmaceuticals, Inc. stock for Q3 2016, up 921% quarter-over-quarter.
- 41 funds opened new CoLucid Pharmaceuticals, Inc. positions in Q3 2016 and 4 closed out, a net change of +37 holders.
- The largest CoLucid Pharmaceuticals, Inc. buyer in Q3 2016 was T. Rowe Price Associates, an estimated $17.1M added.
- The largest CoLucid Pharmaceuticals, Inc. seller in Q3 2016 was Sphera Funds Management, an estimated $1.48M sold.
Based on aggregated 13F filings for Q3 2016.